Lenalidomide and thalidomide in the treatment of chronic pain

Bibliography

• Harden RN, Bruehl S, Stanton-Hicks M, Wilson P. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med 2007;8:326-31
   PubMed Web of Science ®Google Scholar
• de Mos M, de Bruijn AG, Huygen FJ, The incidence of complex regional pain syndrome: a population-based study. Pain 2007;129:12-20
   PubMed Web of Science ®Google Scholar
• de Mos M, Huygen FJ, van der Hoeven-Borgman M, Outcome of the complex regional pain syndrome. Clin J Pain 2009;25:590-7
   PubMed Web of Science ®Google Scholar
• Schwartzma TJ, Alexander GM, Grothusen JR, Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 2009;147:107-15
   PubMed Web of Science ®Google Scholar
• Sigtermans MJ, van Hilten JJ, Bauer MC, Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain 2009;145(30):304-11
   PubMedGoogle Scholar
• Taylor RS, van Buyten JP, Buchser E. Spinal cord stimulation for complex regional pain syndrome: a systematic review of the clinical and cost-effectiveness literature and assessment of the prognostic factors. Eur J Pain 2006;10:91-101
   PubMed Web of Science ®Google Scholar
• van de Vusse AC, Stomp-van den Berg SG, Kessels AH, Weber WE. Randomised controlled trial of gabapentin in complex regional pain syndrome type 1 [ISRCTN84121379]. BMC Neurol 2004;4:13
   PubMed Web of Science ®Google Scholar
• Tran QH, Duong S, Bertini P, Finlayson RJ. Treatment of complex regional pain syndrome: a review of the evidence. Can J Anaesth 2010;57:149-66
   PubMed Web of Science ®Google Scholar
• Mackey S, Feinberg S. Pharmacologic therapies for complex regional pain syndrome. Curr Pain Headache Rep 2007;11:38-43
   PubMedGoogle Scholar
• Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology 2010;113:713-25
   PubMed Web of Science ®Google Scholar
• Orlova IA, Alexander GM, Qureshi RA, MicroRNA modulation in complex regional pain syndrome. J Transl Med 2011;9:195
   PubMed Web of Science ®Google Scholar
• Birklein F. Complex regional pain syndrome. J Neurol 2005;252:131-8
   PubMed Web of Science ®Google Scholar
• Ferreira SH, Lorenzetti BB, Poole S. Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br J Pharmacol 1993;110:1227-31
   PubMed Web of Science ®Google Scholar
• Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett 2008;437:199-202
   PubMed Web of Science ®Google Scholar
• Alexander GM, van Rijn MA, van Hilten JJ, Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005;116:213-19
   PubMed Web of Science ®Google Scholar
• Maihöfner C, Handwerker HO, Neundörfer B, Birklein F. Mechanical hyperalgesia in complex regional pain syndrome: a role for TNF-alpha? Neurology 2005;65:311-13
   PubMed Web of Science ®Google Scholar
• Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, Six years follow- up of the levels of TNF-alpha and IL-6 in patients with complex regional pain syndrome type 1. Mediators Inflamm 2008;2008:469439
   PubMed Web of Science ®Google Scholar
• Uceyler N, Eberle T, Rolke R, Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007;132:14-15
   PubMedGoogle Scholar
• Dirckx M, Stronks DL, Groeneweg G, Huygen FJ. Effect of immunomodulating medications in complex regional pain syndrome: a systematic review. Clin J Pain 2012;38(4):355-63
   Google Scholar
• Manning DC. Immunomodulatory therapies for complex regional pain syndrome: thalidomide and beyond. In: DeLeo JA, Sorkin LS, Watkine LR, editors. Immune and glial regulation of pain. IASP Press, Seattle; 2007. p. 407-16
   Google Scholar
• Braus DF, Krauss JK, Strobel J. The shoulder-hand syndrome after stroke: a prospective clinical trial. Ann Neurol 1994;36:728-33
   PubMed Web of Science ®Google Scholar
• Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids. Acta Chir Scand 1982;148:653-5
   PubMedGoogle Scholar
• Weber D, Rankin K, Gavino M, Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21(1):16-19
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65
   PubMed Web of Science ®Google Scholar
• Teo S, Resztak K, Scheffler M, Thalidomide in the treatment of leprosy. Microbes Infect 2002;4:1193-202
   PubMed Web of Science ®Google Scholar
• Teo SK, Colburn WA, Tracewell WG, Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 2004;43:311-27
   PubMed Web of Science ®Google Scholar
• Corral L, Haslett P, Muller G, Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6
   PubMed Web of Science ®Google Scholar
• D’Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Kong L, Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007;47:1466-75
   PubMed Web of Science ®Google Scholar
• Chen N, Wen L, Lau H, Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol 2012;69:789-97
   PubMed Web of Science ®Google Scholar
• Anderson KC. Lenalidomide and thalidomide: mechanisms of action–similarities and differences. Semin Hematol 2005;42(4 Suppl 4):S3-8
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703
   PubMed Web of Science ®Google Scholar
• Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther 2008;33(3):219-26
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA, Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharm Exp Ther 2003;305:1222-32
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16
   PubMed Web of Science ®Google Scholar
• Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K. Dannenberg AJ. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001;7:3349-55
   PubMed Web of Science ®Google Scholar
• Dirckx M, Stronks DL, Groeneweg G, Huygen FJ. Effect of Immunomodulating medications in complex regional pain syndrome: a systematic review. Clin J Pain 2012;38(4):355-63
   Google Scholar
• Rajkumar S, Fonseca R, Witzig TE. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med 2001;161:2502-3
   PubMed Web of Science ®Google Scholar
• Ching DW, McClintock A, Beswick F. Successful treatment with low-dose thalidomide in a patient with both Behcet's Disease and complex regional pain syndrome type 1: case report. J Clin Rheumatol 2003;9:96-8
   PubMed Web of Science ®Google Scholar
• Schwartzman RJ, Chevlen E, Bengtson K. Thalidomide has activity in treating complex regional pain syndrome. Arch Intern Med 2003;163:1487-8
   PubMed Web of Science ®Google Scholar
• Schwartzman RJ, Irving G, Wallace M, A multicenter, open-label, 12-week study with extension to evaluate the safety and efficacy of lenalidomide (CC-5013) in the treatment of complex regional pain syndrome type-1 [abstract]. 11th World Congress on Pain; IASP Press, Seattle; 2005. p. 580
   Google Scholar
• Levinsky D, Gupta S, Byas-Smith M, Multicenter, double-blind placebo-controlled study evaluating the safety and efficacy of lenalidomide in the treatment of chronic painful radiculopathy. Eur J Pain 2007;11:89
   Google Scholar
• Guarino AH, Silverman T. Using thaliomide in patients with arachnoiditis [abstract]. American Academy of Pain Medicine 23rd Annual meeting; New Orleans, LA; 2007
   Google Scholar
• Goli V, Edwards CL, Uppal P, Fras AM. Thalidomide in the treatment of chronic tension and migraine headache pain: a case study approach. Paper presented at the American Pain Society 25th Annual Scientific Meeting; San Antonio, TX; 3 – 6 May 2006
   Google Scholar
• Lehman TJ, Schechter SJ, Sundel RP, Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr 2004;145:856-7
   PubMed Web of Science ®Google Scholar
• Chagnon AC. Thalidomide for the treatment of refractory post herpetic neuralgia: an open label study. Paper presented at the American Pain Society 24th Annual Scientific Meeting; Boston, MA; March 30 – April 2; 2005
   Google Scholar
• Ades L, Fenaux P. Immunomodulating drugs in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 2011;2011:556-60
   PubMedGoogle Scholar
• Newman L, Johnson E, Staples R. Assessment of the effectiveness of animal developmental toxicity testing for human safety. Reprod Toxicol 1993;7:359-90
   PubMed Web of Science ®Google Scholar
• Mellin G, Katzenstein M. The saga of thalidomide: neuropathy to embryopathy with case reports and congenital abnormalities. N Engl J Med 1962;267:1184-93
   PubMed Web of Science ®Google Scholar
• Tamburini J, Elie C, Park S, Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndrome. Leuk Res 2009;33:547-50
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol 2003;1:194-205
   PubMedGoogle Scholar
• Singhal S, Mehta J, Desikan R, Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma in North America. N Engl J Med 2007;357:2133-42
   PubMed Web of Science ®Google Scholar
• Rodriquez A. Management of the adverse effects of lenalidomide in multiple myeloma. Adv Ther 2011;28:1-10
   Google Scholar
• Revlimid Dosing Guide. Celgene Corp. 2010. Available from: www.revlimid.com/docs/pres_inst.pdf
   Google Scholar
• System for thalidomide education and prescribing safety (S.T.E.P.S.) Celgene Corp. 2007. Available from: www.thalomid.com/steps_program.aspx
   Google Scholar